Imatinib Sandoz (Imatinib)

Imatinib acts on abnormal tyrosine kinase signaling pathways associated with certain hematologic and solid tumors.

• Chronic myeloid leukemia (CML): reduces malignant cell proliferation and improves long‑term survival in patients with BCR‑ABL positive disease.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting the BCR‑ABL kinase driving the leukemia.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking c‑KIT and PDGFR signaling pathways.

• Imatinib binds competitively to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts signal transduction that drives uncontrolled cell division, leading to apoptosis of malignant cells and inhibition of tumor proliferation.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling, often in the extremities.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools.
• Muscle cramps: occasional tightness or pain.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: decreased left‑ventricular ejection fraction.
• Severe neutropenia: markedly low white‑blood‑cell count.
• Anaphylaxis: rare severe allergic reaction.

Patients and prescribers should consider several safety measures before and during therapy.

• Pregnancy: Category D – avoid use unless benefits outweigh risks.
• Breastfeeding: not recommended; drug may pass into milk.
• Hepatic impairment: dose adjustment may be required.
• Cardiac monitoring: assess ejection fraction periodically.
• Drug interactions: review concomitant medications for potential CYP3A4 effects.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Imatinib can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and toxicity.
• Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton‑pump inhibitors: may modestly lower bioavailability.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Vaccines (live attenuated): reduced efficacy; consider timing of administration.